Hematology Reagents - Medical Devices Pipeline Assessment, 2018

Hematology Reagents - Medical Devices Pipeline Assessment, 2018

Summary

GlobalData's Medical Devices sector report, “Hematology Reagents - Medical Devices Pipeline Assessment, 2018 provides an overview of Hematology Reagents currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Hematology Reagents pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Hematology Reagents under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Hematology Reagents and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry.
Reasons to buy

The report enables you to -
  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Hematology Reagents under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product’s current stage of development, territory and estimated launch date.


1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Hematology Reagents Overview
3 Products under Development
3.1 Hematology Reagents - Pipeline Products by Stage of Development
3.2 Hematology Reagents - Pipeline Products by Segment
3.3 Hematology Reagents - Pipeline Products by Territory
3.4 Hematology Reagents - Pipeline Products by Regulatory Path
3.5 Hematology Reagents - Pipeline Products by Estimated Approval Date
4 Hematology Reagents - Pipeline Products under Development by Companies
4.1 Hematology Reagents Companies - Pipeline Products by Stage of Development
4.2 Hematology Reagents - Pipeline Products by Stage of Development
5 Hematology Reagents Companies and Product Overview
5.1 Analyticon Biotechnologies AG Company Overview
5.2 Cellphire Inc Company Overview
5.3 CPSI Biotech Company Overview
5.4 Instrumentation Laboratory Company Overview
5.5 Quotient Limited Company Overview
5.6 Streck Inc Company Overview
5.7 University of California Los Angeles Company Overview
6 Hematology Reagents- Recent Developments
6.1 Jun 12, 2018: Change at the top of the Segment Advanced Therapies at Siemens Healthineers
6.2 Jun 05, 2018: Medtronic Presents Strategic Growth Roadmap at 2018 Investor Day; Outlines Plan to Create Shareholder Value
6.3 Jun 01, 2018: ISBT Satellite Symposium Co-hosted by Ortho Clinical Diagnostics and Quotient Discusses Responding to the Challenges of Resource Constraints in Transfusion Diagnostics
6.4 May 29, 2018: Quotient Names Franz Walt As Chief Executive Officer
6.5 May 29, 2018: Quotient Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Updates on CEO Appointment and MosaiQ European Field Trials
6.6 May 24, 2018: Medtronic Reports Fourth Quarter And Fiscal Year 2018 Financial Results
6.7 May 23, 2018: Swift Biosciences Builds on Momentum, Accelerates Growth with Addition of Nathan Wood as New CEO
6.8 May 14, 2018: Grifols Expands its Blood Typing Solutions Portfolio in the United States with Antisera Reagents
6.9 May 14, 2018: Boule Diagnostics Interim report January - March 2018
6.10 May 09, 2018: Accelerate Diagnostics reports Q1 2018 financial results
6.11 May 09, 2018: Sysmex Group Formulates New Long-Term Management Goals
6.12 May 09, 2018: Sysmex Announces Summary of Consolidated Financial Results for the Fiscal Year Ended March 31, 2018
6.13 May 08, 2018: Haemonetics Appoints Said Bolorforosh Executive Vice President, Chief Technology Officer
6.14 May 08, 2018: Bio-Rad Announces First Quarter 2018 Financial Results
6.15 May 08, 2018: Haemonetics Reports 4th Quarter and Fiscal Year 2018 Results and Provides Fiscal 2019 Guidance
6.16 May 08, 2018: Ortho Clinical Diagnostics Holds Summit to Help Asia-Pacific Lab Leaders Envision the Lab of the Future
6.17 May 07, 2018: Medtronic Appoints Mike Weinstein As Senior Vice President Of Strategy
6.18 May 07, 2018: Instrumentation Laboratory Worldwide Sales Top $970 M In 2017
6.19 May 03, 2018: Siemens Healthineers fully on track to meet the targets
7 Appendix
7.1 Methodology
7.2 About GlobalData
7.3 Contact Us
7.4 Disclaimer
1.1 List of Tables
Table 1: Hematology Reagents - Pipeline Products by Stage of Development
Table 2: Hematology Reagents - Pipeline Products by Segment
Table 3: Hematology Reagents - Pipeline Products by Territory
Table 4: Hematology Reagents - Pipeline Products by Regulatory Path
Table 5: Hematology Reagents - Pipeline Products by Estimated Approval Date
Table 6: Hematology Reagents Companies - Pipeline Products by Stage of Development
Table 7: Hematology Reagents - Pipeline Products by Stage of Development
Table 8: Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview
Table 9: Fluitest IRON B Reagent - Product Status
Table 10: Fluitest IRON B Reagent - Product Description
Table 11: Hemolyzer - 5 - Diff 5P - Product Status
Table 12: Hemolyzer - 5 - Diff 5P - Product Description
Table 13: Hemolyzer - 5 - Diluent - Product Status
Table 14: Hemolyzer - 5 - Diluent - Product Description
Table 15: Hemolyzer-3-Cleaner - Product Status
Table 16: Hemolyzer-3-Cleaner - Product Description
Table 17: Hemolyzer-3-Diluent - Product Status
Table 18: Hemolyzer-3-Diluent - Product Description
Table 19: Hemolyzer-3-Lyser - Product Status
Table 20: Hemolyzer-3-Lyser - Product Description
Table 21: Hemolyzer-5-Lyser - Product Status
Table 22: Hemolyzer-5-Lyser - Product Description
Table 23: Turbitex FER Reagent - Product Status
Table 24: Turbitex FER Reagent - Product Description
Table 25: Cellphire Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 26: Thrombogent - Product Status
Table 27: Thrombogent - Product Description
Table 28: CPSI Biotech Pipeline Products & Ongoing Clinical Trials Overview
Table 29: FACSGuard - Product Status
Table 30: FACSGuard - Product Description
Table 31: Instrumentation Laboratory Company Pipeline Products & Ongoing Clinical Trials Overview
Table 32: HemosIL AcuStar Multi-Ab Controls - Product Status
Table 33: HemosIL AcuStar Multi-Ab Controls - Product Description
Table 34: HemosIL Dabigatran Calibrators - Product Status
Table 35: HemosIL Dabigatran Calibrators - Product Description
Table 36: HemosIL Dabigatran Controls - Product Status
Table 37: HemosIL Dabigatran Controls - Product Description
Table 38: HemosIL Rivaroxaban Calibrators - Product Status
Table 39: HemosIL Rivaroxaban Calibrators - Product Description
Table 40: Quotient Limited Pipeline Products & Ongoing Clinical Trials Overview
Table 41: ALBAcyte Antibody Identification Cells - B - Product Status
Table 42: ALBAcyte Antibody Identification Cells - B - Product Description
Table 43: ALBAcyte Rh - Screening Cells - Product Status
Table 44: ALBAcyte Rh - Screening Cells - Product Description
Table 45: ALBAcyte Screening Cells (2 cell) - Product Status
Table 46: ALBAcyte Screening Cells (2 cell) - Product Description
Table 47: Anti-Human C3 Globulin Reagent - Product Status
Table 48: Anti-Human C3 Globulin Reagent - Product Description
Table 49: Complement Coated Cells - Product Status
Table 50: Complement Coated Cells - Product Description
Table 51: WARM Antibody Removal Reagent - Product Status
Table 52: WARM Antibody Removal Reagent - Product Description
Table 53: Streck Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 54: CD-Chex CD103 Plus - Product Status
Table 55: CD-Chex CD103 Plus - Product Description
Table 56: CD-Chex CD117 Plus - Product Status
Table 57: CD-Chex CD117 Plus - Product Description
Table 58: CD-Chex Select - Product Status
Table 59: CD-Chex Select - Product Description
Table 60: CD-Chex TdT Plus - Product Status
Table 61: CD-Chex TdT Plus - Product Description
Table 62: LBC-Chex - Product Status
Table 63: LBC-Chex - Product Description
Table 64: University of California Los Angeles Pipeline Products & Ongoing Clinical Trials Overview
Table 65: Rh (D) Human Blood Typing Reagent - Product Status
Table 66: Rh (D) Human Blood Typing Reagent - Product Description
Table 67: Glossary
1.2 List of Figures
Figure 1: Hematology Reagents - Pipeline Products by Stage of Development
Figure 2: Hematology Reagents - Pipeline Products by Segment
Figure 3: Hematology Reagents - Pipeline Products by Territory
Figure 4: Hematology Reagents - Pipeline Products by Regulatory Path
Figure 5: Hematology Reagents - Pipeline Products by Estimated Approval Date

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings